Cluster analysis
An analysis of the companies on the map was commissioned by Bidwells and undertaken by Jeanette Walker of letsclilet.com. In addition to providing data about the trends driving the demand for property in the biopharma sector, the study also highlighted key issues that could affect the growth of the cluster and its global competitiveness in the future. These are included in the tables above. The analysis covered the companies in the clusters rather than the universities or hospitals.

Mapping and analysing clusters at this level of detail is challenging, especially as much of the terminology associated with the Biopharma sector is open to interpretation. The map and associated analysis is a snapshot of the cluster as at March 2016 and does not include historical data.

Organisations included on the map
The organisations featured on the map are involved, directly or indirectly, in the Biopharma sector – not the broader life sciences or healthcare sector. They include companies working on products and services aimed at disease prevention, diagnosis, therapeutic interventions and the monitoring of therapeutic treatment outcomes.

Introduction

About clusters
The term business cluster was popularised by Michael Porter in The Competitive Advantage of Nations (1990) who defined clusters as “geographic concentrations of interconnected companies, specialist suppliers, service providers, firms in related industries, and associated institutions (for example universities, standards agencies and trade associations), in particular fields that compete but also cooperate”. The boundary of the cluster for the Cambridge map was set at a 20-mile radius of Great St Mary’s Church. This equates to an area of approximately 1257 square miles (3256 sq km). Only those organisations trading at a postcode within this geography were included.

About Bidwells
At Bidwells we like to think we are a bit different from other property consultants. We don’t claim to do everything for everyone. But we do offer our clients an unparalleled knowledge and access to the markets we serve – and these are some of the most interesting markets with the highest growth potential in the UK.

Much of our work is concentrated in the ‘Golden Triangle’ encompassed by Oxford, Cambridge and London. Key activity in this area is focused on the science & technology, and education sectors. We also manage thousands of square miles of the UK’s countryside and coastline where we are helping clients to take advantage of opportunities in the high performing areas of forestry, renewables, and agriculture.

About letsclilet.com
Founded in 2009, letsclilet.com provides business related consulting services to the biomedical industry. Founder Jeanette Walker has studied biopharma clusters for over 10 years and has played an active role in the development of the Cambridge cluster since 1997.

The information included in this document is believed to be accurate as of March 2016 but no representative or warranty is expressly or impliedly given to its accuracy, completeness or correctness by Bidwells and letsclilet.com limited. No responsibility for financial or other loss resulting from errors or omissions in the information contained in this document is accepted by letsclilet.com limited.

All rights reserved. This publication may not be reproduced in whole or in part without permission of the copyright holders.
Companies working on products and services aimed at disease prevention, diagnostics, therapeutic agents and the monitoring of therapeutic treatment outcomes. Any of the companies could be engaged in one or more of the following activities: discovery/research, development, process development/manufacturing, warehousing, distribution, sales, marketing and consulting.

<table>
<thead>
<tr>
<th>Purpose of technology, product or service</th>
<th>Examples</th>
<th>Category</th>
<th>Excluded</th>
</tr>
</thead>
<tbody>
<tr>
<td>As a therapeutic intervention</td>
<td>Small molecules; biologics; vaccines; cellular therapies, immuno-therapies, gene therapies; tissue engineered products, wound healing and wound care products; regenerative medicine/ stem cell treatments</td>
<td>Therapeutic product</td>
<td>Organisations engaged directly or indirectly in clinical or surgical interventions that do not have an associated medicine or therapy; stents are excluded unless they are drug-eluting stents; self-inflating tissue expander for use in reconstructive surgery</td>
</tr>
<tr>
<td>Monitor health in order to determine whether a person is at risk of requiring a therapeutic agent</td>
<td>Medical devices, diagnostic and other tests used by consumers and/ or healthcare professionals e.g. blood glucose monitors, blood pressure monitors, breath analysers, spirometers, imaging technologies</td>
<td>Therapeutic supply chain</td>
<td>Companies working in the area of functional foods, nutraceuticals; paternity testing</td>
</tr>
<tr>
<td>Administration of a therapeutic agent</td>
<td>Drug delivery devices e.g. patches, inhalers, autoinjectors, needles, nasal sprays etc</td>
<td>Therapeutic supply chain</td>
<td></td>
</tr>
<tr>
<td>Support or facilitate the discovery, research, development, including clinical development, or manufacture of a therapeutic agent</td>
<td>Companies developing, selling or outlicensing a product or service that is based on scientific or clinical expertise. Includes: contract research organisations e.g. analytical services, chemistry, biology, pre-clinical technology platforms e.g. omics, bioinformatics equipment, instrumentation reagents, kits, media, tissues clinical services regulatory affairs technical consultants</td>
<td>Therapeutic supply chain</td>
<td>Tools or equipment used solely to aid surgical intervention not used as part of a therapeutic intervention e.g. stents; medical materials used in surgical instruments</td>
</tr>
<tr>
<td>Determine whether the therapeutic agent has worked</td>
<td>Tests for measuring treatment outcomes; includes imaging products and technologies; patient monitoring; pharmacovigilance</td>
<td>Therapeutic supply chain</td>
<td></td>
</tr>
<tr>
<td>Support the business-related activities of the companies listed above</td>
<td>Specialist strategic, financial or investment advisers e.g. financial due diligence and IP management, medical writing, publishers, marketing communications specialists, market research, business intelligence, investors, technology transfer offices</td>
<td>Business service provider</td>
<td>Patent attorneys, law firms, accountants, general marketing consultants, insurance agents, recruitment consultants, IT/AV consultants, property advisers, facilities managers, architects, web designers, local government, LEPs, logistics</td>
</tr>
</tbody>
</table>
Almost a third of companies established in the last 5 years; current decade on track to be most prolific in terms of number of companies established.

Almost half of all companies based on a science, technology or research park; Babraham Research Campus leader in terms of number of companies.

Ratio of therapeutic product companies to supply chain companies approximately 1:4.

66 companies (about a fifth) are therapeutic product companies; 52 therapeutic product companies (80%) building pipelines in the cluster (pipeline companies); 14 pipeline companies have clinical stage products; cancer treatments most prevalent; novel, small molecule discovery most prolific; 5 immuno-therapy companies.

242 companies in the therapeutic supply chain; instrumentation/equipment largest segment (17%) followed by technical consulting (15%), clinical/regulatory consulting (14%); diagnostics/patient monitoring (13%).

242 companies in the therapeutic supply chain; instrumentation/equipment largest segment (17%) followed by technical consulting (15%), clinical/regulatory consulting (14%); diagnostics/patient monitoring (13%).

Almost half of all companies based on a science, technology or research park; Babraham Research Campus leader in terms of number of companies.

For further information or enquiries please call:

David Williams
Oxford
david.williams@bidwells.co.uk
Tel: 01865 592632

Will Heigham
Cambridge
will.heigham@bidwells.co.uk
Tel: 01223 559443

Jeanette Walker, Director
letscellit.com
Tel: 07540 100512

For a similar analysis of the Oxford Biopharma cluster and associated map please visit www.bidwells.co.uk/research
**Bidwells property market overview**

The refocusing of our business around the ‘Golden Triangle’ of Cambridge–London–Oxford has received a further boost from the recent Centre for Cities Report, which identifies Cambridge and Oxford as amongst the fastest growing cities in the UK.

Cambridge continues as the major focus for the UK’s innovation sector, whilst London and Oxford are also centres for the new tech businesses that are beginning to act as a major driver to the UK’s economic success.

<table>
<thead>
<tr>
<th>Location</th>
<th>Prime headline rent (£psf 12/2015)</th>
<th>Take up (000’s sq ft 12/2015)</th>
<th>Demand (000’s sq ft 12/2015)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cambridge</td>
<td>35.00</td>
<td>552.2</td>
<td>1,432.3</td>
</tr>
<tr>
<td>Cambridge Labs</td>
<td>32.50</td>
<td>657.3</td>
<td>492.0</td>
</tr>
<tr>
<td>Oxford</td>
<td>26.50</td>
<td>204.7</td>
<td>183.0</td>
</tr>
<tr>
<td>London (West End)</td>
<td>125.00</td>
<td>4.3m</td>
<td>N/A</td>
</tr>
</tbody>
</table>

**Prime headline rent**
Prime office rents are up in most locations, with record highs set in Cambridge, Oxford and Milton Keynes.

<table>
<thead>
<tr>
<th>Location</th>
<th>Availability (% total sq ft 12/2015)</th>
<th>Prime yield (% 12/2015)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cambridge</td>
<td>10 ▲</td>
<td>5.0 ▲</td>
</tr>
<tr>
<td>Cambridge Labs</td>
<td>5 ▼</td>
<td>6.0 ▼</td>
</tr>
<tr>
<td>Oxford</td>
<td>9 ▼</td>
<td>5.75 ▼</td>
</tr>
<tr>
<td>London (West End)</td>
<td>5 ▲</td>
<td>3.75 ▼</td>
</tr>
</tbody>
</table>

**Take up**
Take up is down in most markets due largely to supply constraints.

**Availability**
Supply has continued to tighten, with only 600,000 sq ft of grade A space across Bidwells major locations (excluding London).

**Prime Yield**
Prime office yields have hardened as rental growth has returned to provincial centres.

**Demand**
Demand is forecast to drive rental growth over the next 12 months with London, Oxford and Cambridge growing by 8%, 4.7% and 4.3% respectively.
### The cluster
- 352 companies
- 2 universities (University of Cambridge; Anglia Ruskin University)
- 4 (non-university) research institutes (Babraham Institute, Sanger Institute, European Bioinformatics Institute, MRC Laboratory of Molecular Biology)
- 3 NHS Foundation Trusts (Cambridge University Hospitals NHS Foundation Trust; Papworth Hospitals NHS Foundation Trust; Cambridgeshire & Peterborough NHS Foundation Trust)

### Type of companies
- 18% (67) therapeutic product companies
- 68% (242) therapeutic supply chain companies
- 4% (48) business service providers

Ratio of therapeutic product companies to supply chain companies approximately 1:4

Note – some companies are both therapeutic product companies and supply chain companies

### Company size
- 97% (341) employ 250 or fewer people
- 87% (306) employ <50 people
- 3% (9) employ >250 people
- 3 employ >1000 (AstraZeneca, Envigo, Napp/Mundipharma)

6 of the 9 large companies are British
5 of the 9 large companies are therapeutic product companies

### Nationality/ownership
- 84% (293) British
- 16% (57) foreign*
- 74% (258) global HQ
- 20% (71) owned by a single corporate entity;
  5% (16) owned by a holding company
- 9% (30 companies) emerging from the University of Cambridge: 27 in which the University of Cambridge and/or Cambridge Enterprise is, or has been listed as a shareholder on the company’s annual return; plus 3 companies founded around University people and knowledge, but in which the University has no shareholding
- 6% (20) subsidiary of a British company

*Of the 57 foreign companies: 63% (36) are the UK HQ; 54% (31) North America; 51% (29) United States; 32% (18) Europe; 11% (6) Asia Pacific; 4% (2) India

### FINDINGS

#### QUESTIONS ARISING FROM THE STUDY

- What is the optimum size geographically for an area to function as a successful biopharma cluster as defined by Michael Porter?
- How important is it for companies to be, or to be seen to be, part of the Cambridge cluster in terms of attracting investment, staff or establishing credibility?
- At what distance beyond Cambridge would companies consider themselves to be part of the “Cambridge cluster”?
- Is there an optimum ratio of therapeutic product companies to suppliers in a biopharma cluster to ensure sustainability?
- How does the ratio in Cambridge compare with clusters in the US and Europe?
- How important is it to have major pharma in the cluster?
- How are the barriers to growth e.g. availability of suitable or affordable premises; lack of investment or skills; lifestyle choice for people working as freelance consultants?
- To what extent are companies operating a “virtual” model e.g. outsourcing activities to contract research organisations outside the cluster rather than undertaking projects in-house?
- What are the potential threats in having almost a fifth of the companies in foreign ownership?
- In the future, will foreign direct investment from Asia, particularly India and China, increase as these countries seek to acquire innovation?
**FINDINGS**

**Main activity**
- 44% (153) involved in R&D
- 8% (29) engaged in process development, production or manufacturing
- 17% consulting
- 18% scientific services or products
- 17% distribution, sales, marketing

**Age of companies**
- 30% (105) established in last 5 years; compares to 47% (161) in the previous decade
- 12% (41) in the 1990s
- 7% (26) in the 1980s
- 4% before 1980

**Listed companies**
- 7 companies* traded on a stock exchange: 2 therapeutic product companies (GW Pharma and Sareum); 5 supply chain companies (Abcam, Abzena, Cambridge Cognition, Horizon Discovery & Scientific Digital Imaging)
- 4 IPOs took place in the last 5 years: 2 in 2013 and 2 in 2014
- All 7 companies are listed on AIM
- 1 company dual listing AIM & NASDAQ (GW Pharma)
- 2 companies (GW Pharma & Abcam) market cap = $1bn+

*excludes pharma

**Therapeutic product companies**
- 19% of companies (66) are therapeutic product companies
- 5 of the world’s top 10 pharmaceutical companies have a presence in the cluster i.e. AstraZeneca, Sanofi/Genzyme, GSK, J&J (virtual partnering office), Pfizer
- 92% of therapeutic product companies are SMEs
- 38% (25) are in foreign ownership
- 77% (51) are developing product pipelines in Cambridge (pipeline companies)
- 22% (15) pipeline companies have clinical stage products; 59% (30) small molecules; 20% (10) biologics; 12% (6) immuno-therapies
- Anti-cancer drugs most prolific area of discovery

**QUESTIONS ARISING FROM THE STUDY**

**If space in incubator or innovation centres continues to be constrained**
- What are the implications for new companies?

**Will there be sufficient grow-on space for the companies that were established in previous decades?**

**If space is constrained in Cambridge, will companies be prepared to move out of Cambridge e.g. along the Cambridge–Stansted–London corridor?**

**What is the optimum balance of activity in a cluster to secure sustainability?**

**How could more large-scale manufacturing plants be attracted to Cambridge?**

**How does this compare with other clusters?**

**How does it compare with the broader technology sector in Cambridge?**

**What are the barriers to stock market flotations?**

**What are the opportunities and challenges associated with being listed on a stock exchange?**

**Given that most biotech companies license their drugs to pharma, what constitutes success for them e.g. a highvalue trade sale?**

**Why has Cambridge failed to grow companies equivalent in size to companies in the US e.g. Amgen or Gilead?**

**Is Cambridge essentially an R&D laboratory for the pharmaceutical industry? If so, is that “bad” for the cluster?**

**Age of companies**
- 30% (105) companies established in last 5 years; compares to 47% (161) in the previous decade
- 12% (41) in the 1990s
- 7% (26) in the 1980s
- 4% before 1980

**Listed companies**
- 7 companies* traded on a stock exchange: 2 therapeutic product companies (GW Pharma and Sareum); 5 supply chain companies (Abcam, Abzena, Cambridge Cognition, Horizon Discovery & Scientific Digital Imaging)
- 4 IPOs took place in the last 5 years: 2 in 2013 and 2 in 2014
- All 7 companies are listed on AIM
- 1 company dual listing AIM & NASDAQ (GW Pharma)
- 2 companies (GW Pharma & Abcam) market cap = $1bn+

*excludes pharma

**Therapeutic product companies**
- 19% of companies (66) are therapeutic product companies
- 5 of the world’s top 10 pharmaceutical companies have a presence in the cluster i.e. AstraZeneca, Sanofi/Genzyme, GSK, J&J (virtual partnering office), Pfizer
- 92% of therapeutic product companies are SMEs
- 38% (25) are in foreign ownership
- 77% (51) are developing product pipelines in Cambridge (pipeline companies)
- 22% (15) pipeline companies have clinical stage products; 59% (30) small molecules; 20% (10) biologics; 12% (6) immuno-therapies
- Anti-cancer drugs most prolific area of discovery
**FINDINGS**

**Supply chain companies**
- 68% (241) companies
- 86% British; 14% foreign-owned
- 98% SMEs; 87% employ <50 people
- 14% in foreign ownership
- 29% established in last 5 years
- Instrumentation/equipment largest segment (17% of suppliers); 14% clinical/regulatory products or services; 15% technical consulting; 13% diagnostics/patient monitoring; 12% platform technologies; 10% reagents/kits/antibodies

**Business services**
- 14% of cluster (48 companies) including:
  - 30% specialist consultants
  - 3% publishers
  - 12% investment firms/funds
  - 1% industry-specific business network
  - 2% technology transfer offices

**Location**
- 14 science/research/technology parks plus 2 incubators/innovation centres
- Almost half the companies (162) located on a park
- 35% park-based companies located at Babraham Research Campus or 16% of all companies
- Cambridge Science Park and St John’s Innovation Centre home to 14% of all companies

**Management**
- 84% of CEOs are male
- 76% of CEOs are over 50

**Accolades/achievements**
- University of Cambridge world rankings:
  - # 4 overall
  - # 2 in life sciences
  - # 3 in clinical, pre-clinical and health
  - (Times Higher Education World University Rankings 2015-2016)
- 2 companies listed in “FierceBiotech’s Fiercest 15” in the last 5 years – Kymab (2010) and F-star (2011); both developing immuno-therapies

**Finance**
- 16% of companies have attracted equity finance

**QUESTIONS ARISING FROM THE STUDY**

What are the gaps in the supply chain?
How could companies operating in these areas be attracted to the cluster?
How might Cambridge’s academic scientists be encouraged to set up companies to address these gaps?
How can Cambridge exploit the convergence of technologies e.g. information communications technology, engineering, software, physics, astronomy etc?

What is the role of the universities in creating and supporting companies e.g. to provide a skilled workforce for industry?
To what extent have companies in Cambridge been formed from IP sourced from other universities or research institutes?

What are the benefits of locating on a park?
Is there an advantage to being on a dedicated bio park such as Babraham as distinct from a mixed-use park such as the Cambridge Science Park?

What are the barriers to women becoming CEOs and how can these barriers be addressed?
Once the current group of middle aged CEOs retire, will there be a cadre of leaders with the skills and experience to replace them?

How competitive are Cambridge companies globally?
What are the health-related benefits resulting from the cluster?

A detailed examination of investment in the cluster will be published later this year in a separate report.